MetaVia Inc. announced three late-breaking abstracts for the ADA 2026 Scientific Sessions showcasing its cardiometabolic drug candidates: DA-1726, a dual GLP-1/glucagon receptor agonist for obesity, and vanoglipel, a GPR119 agonist for metabolic diseases. DA-1726 is in a Phase 1 trial aiming for higher doses with better tolerability, with results expected in Q4 2026. Vanoglipel shows potential in preclinical studies for treating metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes, including combination therapies. These presentations highlight MetaVia's advancing pipeline targeting weight loss, glucose control, and liver health.
Fitness Champs Holdings Limited (FCHL), penyedia pendidikan olahraga air terkemuka di Singapura, akan mengadakan Rapat Umum Pemegang Saham Luar Biasa (RUPSLB) pada 29 Juni 2026, pukul 10 pagi waktu Singapura. Pemegang saham Kelas A dan Kelas B yang t...
AMD posted strong Q1 results with 37.8% revenue growth and a record $2.57 billion in free cash flow, reinforcing positive investor sentiment. Despite high valuation metrics, the company is expected to benefit from new AI infrastructure products shipp...
The US government is actively negotiating to take equity stakes in AI companies like OpenAI and Anthropic ahead of their planned IPOs, following a precedent set by its investment in Intel. This move aims to give the public a share in AI-driven growth...
CZR Exchange, a global digital asset trading platform, held an invitation-only VIP event on a private yacht during the Monaco Grand Prix 2026. The event brought together top traders, investors, and partners to foster networking and discussions on the...
Trulieve Cannabis Corp. made history by becoming the first U.S. cannabis company to list on the New York Stock Exchange under the ticker TRLV. This milestone was enabled by the Trump administration's reclassification of cannabis to Schedule III for m...
